The International MultiPlE Sclerosis Study (IMPrESS) studied the significant impact of multiple sclerosis (MS) on the health and well-being of both people with the disease and their caregivers, along with its broader socioeconomic impact. Results confirmed that there is an urgent need to achieve better outcomes for people with MS. This paper uses results from the IMPrESS to present new international evidence on the socioeconomic burden of MS and discuss the merits of a likely paradigm shift in the management of MS towards the use of better (and more accurate) diagnostic follow-up to monitor disease progression and the earlier use of disease-modifying treatments (DMTs) to achieve better clinical, quality-of-life and socioeconomic results for individuals.
Introduction
Multiple sclerosis (MS) is the most common cause of disability among central nervous system (CNS) diseases. MS is associated with a high cost of illness, both in terms of direct and indirect costs. Given that the onset of MS is in early adult life (average onset at 29 years of age) lasting over an individual's lifetime, there are huge costs relating to productivity losses. There is also a significant impact on the families of people with MS (PWMS).
Treating until no evidence of disease activity (NEDA) is reached, including no relapses, no increase in disability and no new or active (enhancing) lesions on their magnetic resonance imaging (MRI) scans, is gaining more popularity, 1 and MRI is increasingly more use to diagnose and monitor disease activity in patients on treatment. 2 Meeting this objective implies regular monitoring of not only clinical relapse and disability progression but also MRI activity. However, regular use of MRI to monitor disease activity and the effects of treatment is still not universal, though it is increasingly used as an outcome measure for clinical trials.
There are therapies, such as the disease-modifying treatments (DMTs), which modify the course of the illness. However, considerable neurological damage (some of which may be permanent) can occur if PWMS are not given the appropriate treatment early enough. There is increasing focus on finding ways to identify disease progression as early as possible so that treatments can be adapted to prevent or delay further neurological damage. 2 There is evidence in the recent literature in advocating for an earlier treatment in MS. 3 The International MultiPlE Sclerosis Study (IMPrESS) 4 is the first study that presents the evidence for, and generate debate on, the merits of a policy change in the management of MS, including the use of better (and more accurate) diagnostic follow-up to monitor disease progression and the earlier use of DMTs to achieve better outcomes for individuals and also assess the socioeconomic and personal impact of such a policy change compared to the current status.
The IMPrESS
The IMPrESS used online surveys with PWMS, their caregivers and clinicians as well as secondary data from the literature and health technology assessment (HTA) to produce new international evidence on the socioeconomic burden and health-related quality-oflife (HRQoL) of people affected by MS; the impact that a paradigm shift in the management of MS could have on health outcomes and resource utilisation; the views of PWMS and treating physicians and to explore the factors which influence these views; the criteria driving value assessments of MS pharmaceutical treatments by analysing HTA recommendations and their impact across different settings. This paper summarises the new findings from the surveys and HTA analysis; more details are presented elsewhere. 4 Data presented here refer to a larger sample of responses including an additional wave of data collection completed after the publication of the project report 4 (see Tables 1 and 2 ).
Primary data collection from PWMS, their caregiver and clinicians

Costs
The primary analysis of the PWMS and caregiver data sets provided updated international data on the burden of MS they experience as well as their experience of treatment and support when novel DMTs are available in clinical practice (Table 1) . Total average annual PWMS costs were €41,212 (standard deviation (SD) €18,761). Just over half of total average costs (€21,563) were associated with direct medical costs, followed by indirect costs (€17,492) and direct non-medical costs (€2157). The overall costs (and relative ratio between direct and indirect costs) varied also according to the type of MS and severity of the disease. More severe and disabling cases of secondary-progressive MS (SPMS) were characterised by increased total costs (€49,070) where indirect costs accounted for the majority (about 65%) compared with relapsing-remitting MS (RRMS; about €41914) where indirect costs accounted for about 36%. Similar results are available elsewhere. 5, 6 Caregiver costs related to productivity losses are about double the cost reported by PWMS (€31,653 vs €16,318). More data according to the type of MS and treatment delays are in Appendices 1-4 (Supplementary Material).
Quality of life and how they feel
The average utility value reported was 0.56 (56% of perfect health) based on EuroQol-5-dimensions-5-levels (EQ-5D-5L), with a loss of 28% compared with the general population ( Table 1) . Utilities varied across healthcare systems and types of MS. Comparable estimates were found elsewhere. 6, 7 Greater values in utility were accompanied by lower disability and increased satisfaction values with the healthcare service received. Fatigue and weakness, bladder or balance problems were the most frequently 7 showed that MS-related complications, including severe urinary tract infections, constipation, fractures and falls (due to increased weakness and fatigue) and pressure sores are major reasons for hospital admissions with significant socioeconomic consequences. This highlights the importance of identifying the most appropriate utility measure to be adopted. Caregivers reported better quality of life compared with PWMS (73% vs 59% of perfect health), whereas both caregivers and the person they are caring for reported a mild level of discomfort/ disability.
Exploring the impact that a paradigm shift in the management of MS could have on health outcomes and resource utilisation
Subgroup analysis compared individuals who received early diagnosis of MS (≤12 months from first symptoms) with individuals who received diagnosis later than 12 months after the first symptoms (The cut-off of 12 months adopted here followed current guidance recommending that initiation of a DMT within 12 months of a single neurological attack with MRI-enhancing lesions should be considered as a promising, preventative strategy against future accumulation of disability 1, 2 ). Analysis of the data collected from the PWMS showed that patients treated earlier in the course of the disease showed a trend towards lower total (€39,037 vs €42,996), indirect (€15,733 vs €18,934) and DMT (€19,364 vs €20,491) costs and a higher EQ5D score (0.62 vs 0.56; p < 0.01) compared to those receiving late treatment. For further details, refer Appendices 1-4 (Supplementary Material).
Experience of MS
The majority of PWMS had experience of MS treatment with DMTs from the start of their treatment (80%; 685/856); about 38% of the PWMS were currently receiving DMTs (325/856). Results were comparable with USA data. 8 PWMS were aware of the potential side effects of treatments and may prefer to delay possible risks as much as possible; however, when they discussed the irreversible effect of MS on brain volume and the attached disabilities with their clinician, they may opt for an early intervention. The preferred source of information for PWMS were Internet (MS-specific sites) and clinicians; this is also confirmed in the literature. 8 Although this population was approached online and may be expected to use online resources, only a few of them reported online support groups, social media or online forums as preferred source of information (less than 30% for each type of source).
Both clinicians and patients reported delays between first symptoms and diagnosis (Table 2) . Patients presented mixed views on the outcomes of being treated before receiving diagnosis (avoiding unnecessary disability vs receiving wrong treatment). Although early treatment after diagnosis to maintain NEDA is gaining support as appropriate practice, clinical approaches vary across physician-respondents. Similar key factors of effectiveness, tolerability and safety drive treatment more than costs, route of administration and convenience for both groups. They all recognised that there is more to disease activity than just relapse/disability progression. Results from the PWMS survey showed that half of the respondents preferred to make the final decision about their management of care. Whether a PWMS becomes engaged in their care is a choice for the individual, but clinicians recognise that this should be strongly promoted given the derived health benefits to the PWMS and their increased satisfaction. 8
Analysis of HTAs for MS therapies and the factors influencing decision-making in different settings
New comparative evidence from the HTA assessments on eight different MS treatments (IFNβ-1a IM (Avonex), alemtuzumab (Lemtrada), IFNβ 1a SC (Rebif), glatiramer acetate (COPAXONE), teriflunomide (AUBAGIO), dimethyl fumarate (Tecfidera), fingolimod (Gilenya) and natalizumab (TYSABRI)) conducted across country settings (England, Scotland, Sweden, France, Germany and Canada -see Supplementary Appendices 4 and 6) showed that there is a need for a standardised approach in HTA decision-making when including PWMS' views and a wide range of evidence and outcomes must be considered. Greater homogeneity across HTA bodies is needed when taking into account HRQoL data, and they should include dimensions that patients say have a significant impact on their daily lives but they are not captured by the generic tools (such as EQ-5D-5L) usually adopted by HTA agencies. The lack of real-world data on the clinical and economic benefits of the technology is a key issue commonly reported by HTA bodies. 9 The collection of long-term benefit of DMTs using real-world evidence is a necessary step forward (and currently underway), but should not cause delays to HTA decision-making. Crucially, discussion on an earlier use of DMTs to reduce accumulation of irreversible long-term damage and decrease socioeconomic burden is currently missing from HTA assessment.
Conclusion
The IMPrESS findings demonstrate the need for a comprehensive policy discussion to tackle the problem of improving health outcomes for PWMS. 10 The evidence suggests that this is possible if policy makers address a series of issues to secure the following three main goals: (1) improve the quality of care and health outcomes for every person with MS; (2) A separate online survey (supplemented by face-to-face/telephone discussions) from the PWMS (see Table 1 ) was designed to collect information from clinicians about their experience of MS treatment and support. The target group was MS expert physicians across the participating countries who were approached via personal contacts and patient organisations. A series of MS specialists participating in the conference of the European Association of Neurologist 2015 were also invited to participate. Clinicians' countries of practice included Croatia, Denmark, France, Germany, Greece, Italy, Poland, Russia, Spain, Switzerland, the Netherlands, UK and USA (the total number of questionnaires returned was 94; 49 were suitable for analysis); the PWMS survey was disseminated in Australia, Canada, Czech Republic, Croatia, Estonia, France, Germany, Greece, Italy, Poland, Portugal, Romania, Russia, Serbia, Slovenia, Spain, Sweden, the Netherlands, UK and USA (1152 questionnaires returned; 856 were suitable for analysis).
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